R
Roger Stupp
Researcher at Northwestern University
Publications - 463
Citations - 73077
Roger Stupp is an academic researcher from Northwestern University. The author has contributed to research in topics: Temozolomide & Glioma. The author has an hindex of 93, co-authored 430 publications receiving 63025 citations. Previous affiliations of Roger Stupp include Merck & Co. & University of St. Gallen.
Papers
More filters
Journal ArticleDOI
De novo purine biosynthesis is a major driver of chemoresistance in glioblastoma
Jack Shireman,Fatemeh Atashi,Gina Lee,Eunüs S. Ali,Miranda R. Saathoff,Cheol Park,Sol Savchuk,Shivani Baisiwala,Jason Miska,Maciej S. Lesniak,C. David James,Roger Stupp,Priya Kumthekar,Craig Horbinski,Issam Ben-Sahra,Atique Ahmed +15 more
TL;DR: In this paper, a molecular circuit in which the expression of ciliary protein ADP-ribosylation factor-like protein 13B (ARL13B) is epigenetically regulated to promote adaptation to chemotherapy was identified.
Posted ContentDOI
De-novo purine biosynthesis is a major driver of chemoresistance in glioblastoma
Jack Shireman,Fatameh Atashi,Gina Lee,Eunus S. Ali,Miranda R. Saathoff,Cheol Park,Shivani Baiswala,Jason Miska,Maciej S. Lesniak,J. David,Roger Stupp,Priya Kumthekar,Craig Horbinski,Issam Ben-Sahar,Atique Ahmed +14 more
TL;DR: In this paper, a molecular circuit driven by epigenetic regulation that regulates the expression of ciliary protein ALR13B was identified and demonstrated that ARL13B subsequently interacts with purine biosynthetic enzyme IMPDH2.
Journal ArticleDOI
Medulloblastomas in adults: prognostic factors and lessons from paediatrics.
Cristina Nay Fellay,Didier Frappaz,Marie Pierre Sunyach,Enrico Franceschi,Alba A. Brandes,Roger Stupp +5 more
TL;DR: New molecular subgroups will help tailor treatment and further develop new targeted therapies in adult medulloblastomas patients and should be complemented with new molecular prognostic markers.
Journal ArticleDOI
Promises and controversies in the management of low-grade glioma
Roger Stupp,Brigitta G. Baumert +1 more
Journal ArticleDOI
Multicentre phase II study of imatinib mesylate in patients with recurrent anaplastic oligodendroglioma (AOD)/mixed oligoastrocytoma (MOA) and anaplastic astrocytoma (AA)/low grade astrocytoma (LGA): An EORTC New Drug Development Group (NDDG) and Brain Tumor Group (BTG) study
M. J. van den Bent,A. A. Brandes,Marc Frenay,Pierre Fumoleau,Roger Stupp,C. Dittrich,Bruno Coudert,Paul Clement,Denis Lacombe,Eric Raymond +9 more
TL;DR: It is shown that activation of PDGFα&β receptors yields strong mitogenic effects and activates tumor angiogenesis in malignant gliomas and preclinical data showed tumor growth inhibition of these receptors was inhibited.